Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2007

Abraxis Completes Acquisition of Pfizer Manufacturing Complex

  • Abraxis BioScienc finalized the acquisition of the Pfizer Cruce Dávila manufacturing facility in Barceloneta, Puerto Rico. This 56-acre site consists of a 172,000-sq-ft plant with capabilities of producing injectable pharmaceuticals as well as protein-based biologics and metered-dosed inhalers, according to Abraxis.

    In addition, the acquisition includes a computer-controlled 90,000-sq-ft active pharmaceutical ingredients manufacturing plant and two support facilities with quality assurance and laboratories.

    Under the terms of the agreement, Abraxis will lease the active pharmaceuticals ingredients plant back to Pfizer. Abraxis expects to begin commercial manufacturing from this site in the first half of 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »